Predictive Oncology Inc.

Good day. Thank you for standing by. Welcome to Predictive Oncology's second quarter 2022 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 1, 1 on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Teresa Ferguson, Senior Director of Marketing for Predictive Oncology. Please go ahead.

Thank you. Good morning and thank you to everyone dialing in. We are pleased to be here today. Joining us for the call will be Mel Engel, CEO. Then we'll hear from Bob Myers, CFO, and Dr. Pamela Bush, SVP of Strategic Sales and Business Development. Following our prepared remarks, we will open it up for discussion with questions and answers. You will find the preregistration link for Q&As on the webcast screen. Note that this call will be recorded and includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations, estimates and projections about our industry, our management's beliefs and certain assumptions made by our management. Words such as expects, plans, intends, anticipates, believes, estimates, seeks, variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the US Securities and Exchange Commission. The company's actual results may differ materially from the anticipated results reflected in these forward-looking statements. We'll begin with Predictive Oncology's CEO, Mel Engel.

Thank you, Teresa, and welcome and thank you for joining us for our second quarter shareholder earnings call. Today we will share the latest developments at Predictive Oncology, then we'll give you an overview of last quarter's earnings and end with an update on our commercialization efforts. The first move we made to further strengthen Predictive Oncology's scientific and product strategies is with the appointment of Dr. Julia Kirshner as Chief Scientific Officer. Dr. Kirchner was elevated from her role as Senior Vice President of Predictive Oncology and President of ZPredicta, the company she founded and the company that Predictive Oncology acquired in the fourth quarter of last year. Dr. Kirchner will focus on the integration of Predictive Oncology's product lines and direct future development of our scientific programs. She will also be working closely with Dr. Bush to identify and meet customer needs, as well as provide expanded solutions leveraging artificial intelligence in drug development. Dr. Kirshner is highly respected for her academic and startup experience. Most notably, as he predicted, she is responsible for creating the tumor-specific in vitro 3D models that reconstruct tissue microenvironments and mimic drug response. which is part of our key product line offerings in drug development. Her innovative approach to science and strong background and research make her an ideal fit to lead the long-term vision for Predictive Oncology's product development strategy with Dr. Bush, drive adoption of current Predictive Oncology's assets and guide product iteration. We look forward to bringing more synergy between our businesses and finding opportunities to provide greater value to our customers. Scientific leaders within the company will be reporting in to Dr. Kirshner and she will be working closely with the board of directors to establish a new scientific advisory board. As we move forward, Dr. Kirshner will continue to oversee zPredicta and will transition site leadership in the next three to six months. Our second move is Predictive Oncology's decision to streamline the company's research and development operations, which Dr. Kirshner will oversee. Predictive Oncology will consolidate its tumor genesis division by moving this business from Massachusetts to our flagship location in Pittsburgh, Pennsylvania. By doing this, Predictive Oncology can better focus on growth opportunities with our artificial intelligence technology and lab functions while reducing overhead and centralizing scientific operations. This creates better efficiencies and provides the potential to bring in greater revenue levels as we explore more expanded offerings for clients in the pharmaceutical and biotech industries who are looking to bring more effective cancer treatments to the market. Dr. Bush will share more about the business development and marketing efforts underway. But first, Bob Myers will share about the quarterly earnings. Bob? Thank you, Mel.